Literature DB >> 7189295

Regression of tumors in guinea pigs after treatment with synthetic muramyl dipeptides and trehalose dimycolate.

C A McLaughlin, S M Schwartzman, B L Horner, G H Jones, J G Moffatt, J J Nestor, D Tegg.   

Abstract

A high incidence of tumor regression was observed in guinea pigs bearing transplantable, line-10 hepatocellular carcinomas when synthetic muramyl dipeptides combined with trehalose dimycolate in oil-in-water emulsions were injected directly into the tumors. These compounds are promising candidates to replace viable bacillus Calmette-Guérin in cancer immunotherapy in humans and animals.

Entities:  

Mesh：

Substances：

Year:  1980        PMID： 7189295     DOI： 10.1126/science.7189295

Source DB:  PubMed          Journal:  Science        ISSN： 0036-8075            Impact factor:   47.728


  17 in total

1.  Molecular adjuvants based on nonpyrogenic lipophilic derivatives of norAbuMDP/GMDP formulated in nanoliposomes: stimulation of innate and adaptive immunity.

Authors:  Pavlína Turánek Knotigová; Daniel Zyka; Josef Mašek; Anna Kovalová; Michal Křupka; Eliška Bartheldyová; Pavel Kulich; Štěpán Koudelka; Róbert Lukáč; Zuzana Kauerová; Antonín Vacek; Milada Stuchlová Horynová; Alois Kozubík; Andrew D Miller; Ladislav Fekete; Irena Kratochvílová; Jan Ježek; Miroslav Ledvina; Milan Raška; Jaroslav Turánek
Journal:  Pharm Res       Date:  2015-01-30       Impact factor: 4.200

Review 2.  Muramyl peptides. Chemical structure, biological activity and mechanism of action.

Authors:  A Adam; J F Petit; P Lefrancier; E Lederer
Journal:  Mol Cell Biochem       Date:  1981-12-04       Impact factor: 3.396

3.  Trehalose dimycolate from various mycobacterial species induces differing anti-infectious activities in combination with muramyl dipeptide.

Authors:  K N Masihi; W Brehmer; W Lange; H Werner; E Ribi
Journal:  Infect Immun       Date:  1985-12       Impact factor: 3.441

4.  Enhanced superoxide anion release from phagocytes by muramyl dipeptide or lipopolysaccharide.

Authors:  M Kaku; K Yagawa; S Nagao; A Tanaka
Journal:  Infect Immun       Date:  1983-02       Impact factor: 3.441

5.  Activation of macrophages for enhanced release of superoxide anion and greater killing of Candida albicans by injection of muramyl dipeptide.

Authors:  N P Cummings; M J Pabst; R B Johnston
Journal:  J Exp Med       Date:  1980-12-01       Impact factor: 14.307

6.  Prevention of oncogenic viral infections in mice with CGP 11637, a synthetic muramyl dipeptide analog.

Authors:  H F Acevedo; R B Raikow; H O Acevedo; T F Delgado; M Pardo
Journal:  Antimicrob Agents Chemother       Date:  1985-11       Impact factor: 5.191

7.  Modulation of natural killer cytotoxicity by muramyl dipeptide and trehalose dimycolate incorporated in squalane droplets.

Authors:  K N Masihi; W Lange; B Rohde-Schulz
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

8.  Selective macrophage activation by muramyldipeptide bound to monoclonal antibodies specific for mouse tumor cells.

Authors:  A C Roche; P Bailly; P Midoux; M Monsigny
Journal:  Cancer Immunol Immunother       Date:  1984       Impact factor: 6.968

9.  Inhibition of tumor growth in mice treated with synthetic muramyl dipeptide.

Authors:  J Bubeník; J Jezek; M Zaoral; J Hofmann; Y V Gruntenko; J G Osipov; A G Zolotareva; T E Vakhrusheva; V G Budker
Journal:  Cancer Immunol Immunother       Date:  1984       Impact factor: 6.968

10.  The PorB porin from commensal Neisseria lactamica induces Th1 and Th2 immune responses to ovalbumin in mice and is a potential immune adjuvant.

Authors:  Xiuping Liu; Lee M Wetzler; Paola Massari
Journal:  Vaccine       Date:  2007-12-26       Impact factor: 3.641
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.